2022 World Conference on Lung Cancer (ePosters)-EP08.03-005. HALT - Targeted Therapy with or without Dose-Intensified Radiotherapy in Oligo-Progressive Disease in Oncogene Addicted Lung Tumours

EP08.03-005. HALT - Targeted Therapy with or without Dose-Intensified Radiotherapy in Oligo-Progressive Disease in Oncogene Addicted Lung Tumours

Back to course

Pdf Summary

The HALT trial, funded by Cancer Research UK, aims to assess the use of stereotactic body radiotherapy (SBRT) in patients with oligo-progressive disease (OPD) in oncogene-addicted lung tumors. OPD refers to limited progression observed in patients who initially respond to tyrosine kinase inhibitor (TKI) therapy. The trial is being conducted in 28 centers across the UK and Europe, with a recruitment target of 110 patients. Participating centers have the option to either continue TKI treatment during SBRT or pause TKI treatment during SBRT delivery.<br /><br />The primary endpoint of the trial is progression-free survival (PFS), defined as the time from randomization to disease progression or death. The sample size of 110 patients assumes a median PFS of 3 months in the control group and an additional 3 months benefit with SBRT. The trial incorporates a virtual multidisciplinary meeting (vMDT) to review patient eligibility and assess the suitability of progressive lesions for SBRT.<br /><br />The vMDT review process has identified common reasons for ineligibility, such as too many progressive lesions or lesions unsuitable for SBRT. Amendments to the protocol have been made to increase the potentially eligible patient population, including the inclusion of PET avid only lesions. The trial also includes a formal safety review to assess the impact of SBRT on radiotherapy toxicity and disease flare.<br /><br />The HALT trial will provide valuable information on the efficacy and safety of SBRT in patients with OPD, informing future trial design and contributing to the development of international guidelines for the management of oligoprogression in lung cancer. The trial is ongoing, with data from the vMDT indicating the reasons for patient ineligibility. The trial management group is grateful for the support from the participating centers and the National Radiotherapy Trials Quality Assurance Team.

Asset Subtitle

Fiona McDonald

Meta Tag

Speaker Fiona McDonald

Topic Metastatic Non-small Cell Lung Cancer Oligometastatic Disease

Keywords

HALT trial

SBRT

OPD

tyrosine kinase inhibitor

PFS

recruitment target

vMDT

progressive lesions

radiotherapy toxicity

lung cancer